Find Betahistine Dihydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

JP

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

0

Australia

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 5579-84-0, Betahistine hydrochloride, Betahistine 2hcl, Betahistine hcl, Serc, Betaserc
Molecular Formula
C8H14Cl2N2
Molecular Weight
209.11  g/mol
InChI Key
XVDFMHARQUBJRE-UHFFFAOYSA-N
FDA UNII
49K58SMZ7U

Betahistine Dihydrochloride
A histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.
1 2D Structure

Betahistine Dihydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-methyl-2-pyridin-2-ylethanamine;dihydrochloride
2.1.2 InChI
InChI=1S/C8H12N2.2ClH/c1-9-7-5-8-4-2-3-6-10-8;;/h2-4,6,9H,5,7H2,1H3;2*1H
2.1.3 InChI Key
XVDFMHARQUBJRE-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CNCCC1=CC=CC=N1.Cl.Cl
2.2 Other Identifiers
2.2.1 UNII
49K58SMZ7U
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Aequamen

2. Betahistin Al

3. Betahistin Ratiopharm

4. Betahistin Stada

5. Betahistin-ratiopharm

6. Betahistine

7. Betahistine Biphar

8. Betahistine Dihydrobromide

9. Betahistine Hydrochloride

10. Betahistine Mesylate

11. Betahistine Methanesulfonate

12. Betahistine Methanesulphonate

13. Betaserc

14. Betavert

15. By Vertin

16. By-vertin

17. Dihydrobromide, Betahistine

18. Dihydrochloride, Betahistine

19. Extovyl

20. Fidium

21. Hydrochloride, Betahistine

22. Lectil

23. Melopat

24. Mersilon

25. Mesylate, Betahistine

26. Methanesulfonate, Betahistine

27. Methanesulphonate, Betahistine

28. Pt 9

29. Pt-9

30. Pt9

31. Ribrain

32. Serc

33. Vasomotal

34. Vertigon

2.3.2 Depositor-Supplied Synonyms

1. 5579-84-0

2. Betahistine Hydrochloride

3. Betahistine 2hcl

4. Betahistine Hcl

5. Serc

6. Betaserc

7. Microser

8. Antivom

9. 2-pyridineethanamine, N-methyl-, Dihydrochloride

10. Betahistine (dihydrochloride)

11. Pt-9

12. 2-(2-(methylamino)ethyl)pyridine Dihydrochloride

13. Betahistine Hydrochloride [usan:usp]

14. Beta-histine Dihdrochloride

15. N-methyl-n-(2-pyridin-2-ylethyl)amine Dihydrochloride

16. 5579-84-0 (hcl)

17. 49k58smz7u

18. Methyl[2-(2-pyridyl)ethyl]amine Dihydrochloride

19. N-methyl-2-pyridin-2-ylethanamine;dihydrochloride

20. Veserc

21. Mfcd00012813

22. N-methyl-2-(pyridin-2-yl)ethanamine Dihydrochloride

23. Nsc-757397

24. Methyl[2-(pyridin-2-yl)ethyl]amine Dihydrochloride

25. Novo-betahistine

26. Pt 9

27. Betahistine Hydrochloride [usan]

28. Einecs 226-966-5

29. Unii-49k58smz7u

30. Betahistine Dihcl

31. Betahistine Di Hcl

32. Serc (tn)

33. Beta-histine Dihydrochloride

34. N-methyl-2-pyridin-2-ylethanamine Dihydrochloride

35. Schembl60646

36. Spectrum1500670

37. Betahistine Hydrochloride ,(s)

38. Betahistine Hydrochloride (usp)

39. Chembl1446813

40. Hy-b0524a

41. Betahistine Dihydrochloride, 97%

42. Dtxsid10204355

43. Amy40800

44. Bcp13779

45. Ccg-40327

46. S3176

47. Akos015891507

48. Ks-5298

49. Nsc 757397

50. 2-(2-(methylamino)ethyl)pyridine 2hcl

51. Betahistine Dihydrochloride [mi]

52. Betahistine Hydrochloride [mart.]

53. Betahistine Hydrochloride [vandf]

54. Ncgc00095910-01

55. Betahistine Hydrochloride [usp-rs]

56. Betahistine Hydrochloride [who-dd]

57. Db-052800

58. Ft-0622911

59. Ft-0663076

60. Sw196969-3

61. En300-31560

62. 79b840

63. D03102

64. Betahistine Hydrochloride [usp Monograph]

65. A830811

66. Betahistine Dihydrochloride [ep Monograph]

67. N-methyl-2-(2-pyridinyl)ethanamine Dihydrochloride

68. N-methyl-2-(pyridin-2-yl)ethanaminedihydrochloride

69. N-methyl-2-pyridin-2-yl-ethanamine Dihydrochloride

70. Q27259291

71. Betahistine Dihydrochloride, European Pharmacopoeia (ep) Reference Standard

72. Betahistine Hydrochloride, United States Pharmacopeia (usp) Reference Standard

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 209.11 g/mol
Molecular Formula C8H14Cl2N2
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count2
Rotatable Bond Count3
Exact Mass208.0534038 g/mol
Monoisotopic Mass208.0534038 g/mol
Topological Polar Surface Area24.9 Ų
Heavy Atom Count12
Formal Charge0
Complexity83.3
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Histamine Agonists

Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically. (See all compounds classified as Histamine Agonists.)


Vasodilator Agents

Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)


Drugs in Development

read-more
read-more

Details:

Betahistine dihydrochloride is an antivertigo agent, which is act as the histamine receptor inhibitor, which is indicated for the reduction of recurrent vertigo episodes associated with Meniere's disease in patients 18 years old and above.


Lead Product(s): Betahistine Dihydrochloride,Inapplicable

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Betahistine Dihydrochloride-Generic

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 03, 2023

blank

01

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : Betahistine dihydrochloride is an antivertigo agent, which is act as the histamine receptor inhibitor, which is indicated for the reduction of recurrent vertigo episodes associated with Meniere's disease in patients 18 years old and above.

Product Name : Betahistine Dihydrochloride-Generic

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 03, 2023

blank

Details:

AM-125 is a patented intranasal formulation of betahistine dihydrochloride. It has been shown to have 5 to 29 times higher bioavailability than orally administeration. It is being developed for the treatment of acute vestibular syndrome.


Lead Product(s): Betahistine Dihydrochloride,Inapplicable

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 15, 2023

blank

02

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : AM-125 is a patented intranasal formulation of betahistine dihydrochloride. It has been shown to have 5 to 29 times higher bioavailability than orally administeration. It is being developed for the treatment of acute vestibular syndrome.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 15, 2023

blank

Details:

AM-125 is a patented intranasal formulation of betahistine. It has been shown to have 5-to-29 times higher bioavailability than orally administeration. It is being developed for the treatment of acute vestibular syndrome.


Lead Product(s): Betahistine Dihydrochloride,Inapplicable

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 12, 2023

blank

03

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : AM-125 is a patented intranasal formulation of betahistine. It has been shown to have 5-to-29 times higher bioavailability than orally administeration. It is being developed for the treatment of acute vestibular syndrome.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 12, 2023

blank

Details:

AM-125 is a patented intranasal formulation of betahistine dihydrochloride. It has been shown to have 5-to-29 times higher bioavailability than orally administeration. It is being developed for the treatment of acute vestibular syndrome.


Lead Product(s): Betahistine Dihydrochloride,Inapplicable

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 10, 2023

blank

04

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : AM-125 is a patented intranasal formulation of betahistine dihydrochloride. It has been shown to have 5-to-29 times higher bioavailability than orally administeration. It is being developed for the treatment of acute vestibular syndrome.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 10, 2023

blank

Details:

In Part B of the TRAVERS trial, the Company will enroll 72 patients who suffer from acute peripheral vertigo following neurosurgery. They are randomized to receive either 10 or 20 mg of intranasal betahistine or a placebo three times daily for four weeks.


Lead Product(s): Betahistine Dihydrochloride,Inapplicable

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 14, 2021

blank

05

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : In Part B of the TRAVERS trial, the Company will enroll 72 patients who suffer from acute peripheral vertigo following neurosurgery. They are randomized to receive either 10 or 20 mg of intranasal betahistine or a placebo three times daily for four weeks...

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 14, 2021

blank

Details:

First patient has been randomized in Part B of its “TRAVERS” Phase 2 trial of AM-125 (intranasal betahistine) in acute vertigo. This follows the positive read-out from the interim analysis on Part A of the study in early September 2020.


Lead Product(s): Betahistine Dihydrochloride,Inapplicable

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 13, 2020

blank

06

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : First patient has been randomized in Part B of its “TRAVERS” Phase 2 trial of AM-125 (intranasal betahistine) in acute vertigo. This follows the positive read-out from the interim analysis on Part A of the study in early September 2020.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 13, 2020

blank

Details:

Interim analysis of Phase 2 “TRAVERS” trial demonstrated a dose-dependent improvement in balance as well as good safety and tolerability of ascending doses of AM-125.


Lead Product(s): Betahistine Dihydrochloride,Inapplicable

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 03, 2020

blank

07

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : Interim analysis of Phase 2 “TRAVERS” trial demonstrated a dose-dependent improvement in balance as well as good safety and tolerability of ascending doses of AM-125.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 03, 2020

blank

Details:

Auris Medical Holding completed patient enrollment into Part A of its Phase 2 “TRAVERS” trial with intranasal betahistine in vertigo (AM-125). The Company expects to release interim results from TRAVERS and commence Part B of the trial in the coming weeks.


Lead Product(s): Betahistine Dihydrochloride,Inapplicable

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 29, 2020

blank

08

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : Auris Medical Holding completed patient enrollment into Part A of its Phase 2 “TRAVERS” trial with intranasal betahistine in vertigo (AM-125). The Company expects to release interim results from TRAVERS and commence Part B of the trial in the coming ...

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 29, 2020

blank

Details:

Last subject had last treatment visit in Phase 1b trial with AM-201 in prevention of antipsychotic-induced weight gain and somnolence; data read-out expected for early May 2020.


Lead Product(s): Betahistine Dihydrochloride,Inapplicable

Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 05, 2020

blank

09

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : Last subject had last treatment visit in Phase 1b trial with AM-201 in prevention of antipsychotic-induced weight gain and somnolence; data read-out expected for early May 2020.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 05, 2020

blank

Details:

Betahistine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Vertigo.


Lead Product(s): Betahistine Dihydrochloride,Inapplicable

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 09, 2019

blank

10

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : Betahistine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Vertigo.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 09, 2019

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Betahistine

Brand Name : Betahistin Abacus Medicine

Dosage Form : Tablet

Dosage Strength : 16 mg

Packaging :

Approval Date : 07-11-2025

Application Number : 2.03E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

02

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Betahistine

Brand Name : Betaserc®

Dosage Form : Tablet

Dosage Strength : 8mg

Packaging :

Approval Date : 29-12-2022

Application Number :

Regulatory Info :

Registration Country : Moldova

blank

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Brand Name : Betahistine

Dosage Form : Tablet

Dosage Strength : 8MG

Packaging :

Approval Date : 2014-07-23

Application Number :

Regulatory Info : Authorised

Registration Country : Malta

blank

04

Sandoz A/S

Switzerland
AACR Annual meeting
Not Confirmed
arrow

Sandoz A/S

Switzerland
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Brand Name : Betahistine \"Sandoz\"

Dosage Form : Tablet

Dosage Strength : 16mg

Packaging :

Approval Date : 12-03-2021

Application Number : 28106384820

Regulatory Info : Prescription

Registration Country : Denmark

blank

05

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Brand Name : Betahistina Stadagen

Dosage Form : Tablet

Dosage Strength : 8MG

Packaging :

Approval Date : 05-03-2025

Application Number : 90196

Regulatory Info : Authorized

Registration Country : Spain

blank

06

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Brand Name : Betahistina Stadafarma

Dosage Form : Tablet

Dosage Strength : 8MG

Packaging :

Approval Date : 16-05-2019

Application Number : 84132

Regulatory Info : Cancelled

Registration Country : Spain

blank

07

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Brand Name : Betahistine Stada

Dosage Form : Tablet

Dosage Strength : 8mg

Packaging :

Approval Date : 04-06-2019

Application Number : 2.02E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

08

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Brand Name : Menisci

Dosage Form : Tablet

Dosage Strength : 16mg

Packaging :

Approval Date : 05-02-2025

Application Number : 2.02E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

09

SOLVAY PHARMA SpA

Country
AACR Annual meeting
Not Confirmed
arrow

SOLVAY PHARMA SpA

Country
arrow
AACR Annual meeting
Not Confirmed

Betahistine

Brand Name : Vertiserc

Dosage Form :

Dosage Strength : 50 Cpr 8 Mg  

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

10

SOLVAY PHARMA SpA

Country
AACR Annual meeting
Not Confirmed
arrow

SOLVAY PHARMA SpA

Country
arrow
AACR Annual meeting
Not Confirmed

Betahistine

Brand Name : Vertiserc

Dosage Form :

Dosage Strength : 20 Cpr 16 Mg  

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Regulatory FDF Prices

read-more
read-more

01

Brand Name : Betahistine

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Brand Name : Betahistine

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Dosage Form :

Dosage Strength : 50 Cpr 8 Mg  

Price Per Pack (Euro) : 9.5

Published in :

Country : Italy

RX/OTC/DISCN : Class C

blank

02

Brand Name : Betahistine

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Brand Name : Betahistine

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Dosage Form :

Dosage Strength : 20 Cpr 16 Mg  

Price Per Pack (Euro) : 7.5

Published in :

Country : Italy

RX/OTC/DISCN : Class C

blank

03

Brand Name : Betahistine

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Brand Name : Betahistine

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Dosage Form :

Dosage Strength : 30 Cpr 16 Mg  

Price Per Pack (Euro) : 11.25

Published in :

Country : Italy

RX/OTC/DISCN : Class C

blank

04

Brand Name : Betahistine

Country
arrow
AACR Annual meeting
Not Confirmed

Brand Name : Betahistine

Country
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Dosage Form :

Dosage Strength : 50 Cpr 8 Mg  

Price Per Pack (Euro) : 9.5

Published in :

Country : Italy

RX/OTC/DISCN : Class C

blank

05

Brand Name : Betahistine

Country
arrow
AACR Annual meeting
Not Confirmed

Brand Name : Betahistine

Country
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Dosage Form :

Dosage Strength : 20 Cpr 16 Mg  

Price Per Pack (Euro) : 7.5

Published in :

Country : Italy

RX/OTC/DISCN : Class C

blank

06

Brand Name : Betahistine

Country
arrow
AACR Annual meeting
Not Confirmed

Brand Name : Betahistine

Country
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Dosage Form :

Dosage Strength : 20 Cpr 16 Mg  

Price Per Pack (Euro) : 7.69

Published in :

Country : Italy

RX/OTC/DISCN : Class C

blank

07

Brand Name : Sincrover

Country
arrow
AACR Annual meeting
Not Confirmed

Brand Name : Sincrover

Country
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Dosage Form :

Dosage Strength : 50 Cpr 8 Mg  

Price Per Pack (Euro) : 11.22

Published in :

Country : Italy

RX/OTC/DISCN : Class C

blank

08

Brand Name : Sincrover

Country
arrow
AACR Annual meeting
Not Confirmed

Brand Name : Sincrover

Country
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Dosage Form :

Dosage Strength : 20 Cpr 16 Mg  

Price Per Pack (Euro) : 9.18

Published in :

Country : Italy

RX/OTC/DISCN : Class C

blank

09

Brand Name : Microser

Country
arrow
AACR Annual meeting
Not Confirmed

Brand Name : Microser

Country
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Dosage Form :

Dosage Strength : 50 Cpr 8 Mg  

Price Per Pack (Euro) : 11.95

Published in :

Country : Italy

RX/OTC/DISCN : Class C

blank

10

Brand Name : Microser

Country
arrow
AACR Annual meeting
Not Confirmed

Brand Name : Microser

Country
arrow
AACR Annual meeting
Not Confirmed

Betahistine Dihydrochloride

Dosage Form :

Dosage Strength : 30 Cpr 16 Mg  

Price Per Pack (Euro) : 13.5

Published in :

Country : Italy

RX/OTC/DISCN : Class C

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 5579-84-0 / Betahistine Dihydrochloride API manufacturers, exporters & distributors?

Betahistine Dihydrochloride manufacturers, exporters & distributors 1

86

PharmaCompass offers a list of Betahistine Dihydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Betahistine Dihydrochloride manufacturer or Betahistine Dihydrochloride supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Betahistine Dihydrochloride manufacturer or Betahistine Dihydrochloride supplier.

API | Excipient name

Betahistine Dihydrochloride

Synonyms

5579-84-0, Betahistine hydrochloride, Betahistine 2hcl, Betahistine hcl, Serc, Betaserc

Cas Number

5579-84-0

Unique Ingredient Identifier (UNII)

49K58SMZ7U

About Betahistine Dihydrochloride

A histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.

Betahistine Dihydrochloride Manufacturers

A Betahistine Dihydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Betahistine Dihydrochloride, including repackagers and relabelers. The FDA regulates Betahistine Dihydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Betahistine Dihydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Betahistine Dihydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Betahistine Dihydrochloride Suppliers

A Betahistine Dihydrochloride supplier is an individual or a company that provides Betahistine Dihydrochloride active pharmaceutical ingredient (API) or Betahistine Dihydrochloride finished formulations upon request. The Betahistine Dihydrochloride suppliers may include Betahistine Dihydrochloride API manufacturers, exporters, distributors and traders.

click here to find a list of Betahistine Dihydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Betahistine Dihydrochloride USDMF

A Betahistine Dihydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Betahistine Dihydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Betahistine Dihydrochloride DMFs exist exist since differing nations have different regulations, such as Betahistine Dihydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Betahistine Dihydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Betahistine Dihydrochloride USDMF includes data on Betahistine Dihydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Betahistine Dihydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Betahistine Dihydrochloride suppliers with USDMF on PharmaCompass.

Betahistine Dihydrochloride KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Betahistine Dihydrochloride Drug Master File in Korea (Betahistine Dihydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Betahistine Dihydrochloride. The MFDS reviews the Betahistine Dihydrochloride KDMF as part of the drug registration process and uses the information provided in the Betahistine Dihydrochloride KDMF to evaluate the safety and efficacy of the drug.

After submitting a Betahistine Dihydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Betahistine Dihydrochloride API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Betahistine Dihydrochloride suppliers with KDMF on PharmaCompass.

Betahistine Dihydrochloride CEP

A Betahistine Dihydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Betahistine Dihydrochloride Certificate of Suitability (COS). The purpose of a Betahistine Dihydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Betahistine Dihydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Betahistine Dihydrochloride to their clients by showing that a Betahistine Dihydrochloride CEP has been issued for it. The manufacturer submits a Betahistine Dihydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Betahistine Dihydrochloride CEP holder for the record. Additionally, the data presented in the Betahistine Dihydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Betahistine Dihydrochloride DMF.

A Betahistine Dihydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Betahistine Dihydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Betahistine Dihydrochloride suppliers with CEP (COS) on PharmaCompass.

Betahistine Dihydrochloride WC

A Betahistine Dihydrochloride written confirmation (Betahistine Dihydrochloride WC) is an official document issued by a regulatory agency to a Betahistine Dihydrochloride manufacturer, verifying that the manufacturing facility of a Betahistine Dihydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Betahistine Dihydrochloride APIs or Betahistine Dihydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Betahistine Dihydrochloride WC (written confirmation) as part of the regulatory process.

click here to find a list of Betahistine Dihydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.

Betahistine Dihydrochloride NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Betahistine Dihydrochloride as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Betahistine Dihydrochloride API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Betahistine Dihydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Betahistine Dihydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Betahistine Dihydrochloride NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Betahistine Dihydrochloride suppliers with NDC on PharmaCompass.

Betahistine Dihydrochloride GMP

Betahistine Dihydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Betahistine Dihydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Betahistine Dihydrochloride GMP manufacturer or Betahistine Dihydrochloride GMP API supplier for your needs.

Betahistine Dihydrochloride CoA

A Betahistine Dihydrochloride CoA (Certificate of Analysis) is a formal document that attests to Betahistine Dihydrochloride's compliance with Betahistine Dihydrochloride specifications and serves as a tool for batch-level quality control.

Betahistine Dihydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Betahistine Dihydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Betahistine Dihydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Betahistine Dihydrochloride EP), Betahistine Dihydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Betahistine Dihydrochloride USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty